Bendamustine (hydrochloride)

Bendamustine hydrochloride (SDX-105), a purine analogue, is a DNA cross-linking agent. Bendamustine hydrochloride activats DNA-damage stress response and apoptosis. Bendamustine hydrochloride has potent alkylating, anticancer and antimetabolite properties[1].

Product Specifications

CAS Number

[3543-75-7]

Product Name Alternative

SDX-105

UNSPSC

12352005

Hazard Statement

H301, H351, H360

Target

Apoptosis; DNA Alkylator/Crosslinker

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bendamustine-hydrochloride.html

Purity

99.89

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 10 mg/mL (ultrasonic)

Smiles

CN1C(C=CC(N(CCCl)CCCl)=C2)=C2N=C1CCCC(O)=O.Cl

Molecular Formula

C16H22Cl3N3O2

Molecular Weight

394.72

Precautions

H301, H351, H360

References & Citations

[1]Leoni LM, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1;14 (1) :309-17.|[2]Cives M, et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013 May;25 (5) :1108-17.|[3]Ackler S, et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol. 2012 Oct;167 (4) :881-91.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture and light)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Cell Rep Med. 2025 Apr 2:102053.|J Biomed Res. 2017 0 (0) : 1-12.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Patent. US20160222465A1.|Leukemia. 2023 Nov;37 (11) :2221-2230.